Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
Authors: Grimm P1, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, et all.
<a href="https://isoray.com/research-category/brachytherapy/">Brachytherapy</a>, <a href="https://isoray.com/research-category/featured/">Featured</a>, <a href="https://isoray.com/research-category/brachytherapy/prostate/">Prostate</a>
“Cesium provides everything we want for prostate brachytherapy as both a monotherapy and in combination therapy, including delivery of a high dose of radiation more quickly for high risk patients in a low dose rate ‘setting.’”